SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is trending as investors monitor technical indicators for a potential breakout, with the community actively debating whether it is positioned for a significant rally alongside broader crypto market momentum. While some traders express frustration with current price consolidation, many are highlighting historical patterns and potential institutional adoption as catalysts for future growth.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is generating significant community buzz as traders track its correlation with broader crypto market trends and monitor key technical resistance levels. Sentiment is heavily driven by ecosystem developments, new token launches, and ongoing debates regarding Solana's long-term performance compared to other major digital assets.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

MullenArmy is rallying around the $MULN crypto token as community members actively trade, discuss potential momentum, and promote the asset across social channels. While some participants are hyping a bullish outlook and drawing parallels to previous community-led surges, others are expressing skepticism and warning of risks associated with its historical performance and association with the EV-themed stock.

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

TransCode Therapeutics Inc

TransCode Therapeutics is trending following a significant corporate restructuring that includes the acquisition of Polynoma and a strategic $25 million financing deal, prompting intense community debate over potential dilution versus long-term growth. Investors are closely monitoring clinical trial developments as the company seeks to advance its oncology pipeline, with active discussions focusing on the stock's low float and high sensitivity to potential short-squeeze activity.

noice

NOICE is trending as traders speculate on its potential for volatility and explosive growth, fueled by its status as a nanocap meme token and recent appearances on trending gainers lists. The community is actively debating its technical setup, sharing hopes for further exchange visibility, and discussing broader market sentiment regarding altcoin season and upcoming regulatory developments.

$ORDI : first token deployed on Bitcoin Ordinals, with a 21 million supply. $DOGI : first token deployed on Dogecoin Ordinals, with a 21 million supply. The First DRC-20 token in the history

dogi

DOGI is gaining momentum as the first DRC-20 token on the Dogecoin network, with community members actively accumulating the asset alongside Dogecoin. Traders are highlighting the upcoming launch of Doge OS and rising transaction volumes as key catalysts driving sentiment around the project's utility and market potential.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing significant engagement as traders debate its long-term potential amid a broader crypto market rotation into AI and IoT-related narratives. While some in the community are actively accumulating, others are voicing frustration over stagnant price action and expressing skepticism regarding project leadership and ecosystem partnerships.

BRETT the dancer, gamer, and cultural icon of BASE chain (some like to call me the PEPE of BASE).

Brett

Brett holders are actively debating the token's long-term viability as it faces significant price volatility and stiff competition for the 'Face of Base' title from projects like Toshi. While some community members view current dips as a prime opportunity for accumulation ahead of potential exchange listings, others are rotating capital into competitors due to concerns over stagnant growth and lack of utility.

The Real FartCoin as suggested by Truth Terminal, following the "FartCoin Launch Strategy". Full FartCoin Ecosystem with a major focus on Planting Trees across the world.  FartNFTs,FartDAO,FartSwap and many other applications are part of our movement. With the also correct Token Mechanics such as the correct Ticker, Supply, Blockchain and Purpose of the token.  Community ran and funded, with great intentions to follow up with the full "lore" of the FartCoin!

FartCoin

FartCoin is currently a focal point for the meme coin community, drawing significant debate over whether it represents a legitimate market asset or a speculative gamble. Traders are actively monitoring the token's technical support levels and volume trends while comparing its community engagement to other established altcoins and speculative market trends.

Brinker International, Inc. engages in owning, developing, and franchising Chili's Grill and Bar and Maggiano's Little Italy restaurant brands. It operates through the Chili's and Maggiano's segments. The Chili's segment includes the results of company-owned Chili's restaurants in the U.S. and Canada as well as the results from its domestic and international franchise business. The Maggiano's segment refers to the results of company owned Maggiano's restaurants. The company was founded by Larry Lavine on March 13, 1975 and is headquartered in Dallas, TX.

Brinker International, Inc.

Brinker International is trending as investors rally behind a successful turnaround at Chili's, driven by effective viral marketing, a simplified menu, and strong traffic growth that is bucking broader sector headwinds. The community is actively discussing the company's robust operational execution, consistent earnings beats, and the potential for long-term margin expansion.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cybin (NASDAQ:HELP) Shares Up 2.7%  - Should You Buy?

Cybin (NASDAQ:HELP) Shares Up 2.7% - Should You Buy...

<ul class="summary-bullets"><li>The FDA stated that it will issue national priority vouchers to three companies studying psilocybin for the treatment of treatment-resistant depression and major depressive disorder, and methylone for the treatment of PTSD.</li><li>The agency stated that it has also cleared DemeRx NB’s early-stage clinical trial of noribogaine hydrochloride for potential treatment of alcohol use disorder to proceed following an Investigational New Drug submission.</li><li>Compass Pathways announced that it has been awarded a national priority voucher for COMP360, its proprietary formulation of synthetic psilocybin for treatment-resistant depression.</li></ul>The U.S. Food and Drug Administration (FDA) on Friday announced several regulatory actions to accelerate the development of psychedelic treatments aimed at serious mental health issues.The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.“Under President Trump’s leadership, we are accelerating the research, approval, and responsible access to promising mental health treatments—including psychedelic therapies like ibogaine—to confront our nation’s mental health crisis head-on, especially for our veterans,” said Health and Human Services Secretary Robert F. Kennedy, Jr.This comes after President Trump signed an executive order last week that directed health agencies to speed up research on drugs like psilocybin, MDMA, and ibogaine.Shares of&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences Inc.</a> (ENVB) skyrocketed over 62% in Friday morning’s trade, while&nbsp;<a href="https://stocktwits.com/symbol/CMPS">Compass Pathways Plc.</a> (CMPS) and&nbsp;<a href="https://stocktwits.com/symbol/HELP">Helus Pharma Inc.</a> (HELP) and&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences Inc.</a> (ENVB) rose between 2% to 3%.<h2 class="st-heading-2">FDA To Issue National Priority Vouchers</h2>The FDA stated that it will issue national priority vouchers to three companies studying psilocybin for the treatment of treatment-resistant depression and major depressive disorder, and methylone for the treatment of PTSD.Compass Pathways announced that it has been awarded a national priority voucher for COMP360, its proprietary formulation of synthetic psilocybin for treatment-resistant depression.The agency stated that it has also cleared an early-stage clinical trial of noribogaine hydrochloride for potential treatment of alcohol use disorder to proceed following an Investigational New Drug (IND) submission.This is the first time the FDA has permitted a U.S.-based clinical study of an ibogaine derivative, enabling the developer of the novel therapy, DemeRx NB, to initiate a Phase 1 trial in a closely monitored clinical setting in the United States.RFK Jr. said the agency will prioritize therapies with Breakthrough Therapy designation, for which early evidence shows meaningful improvement over existing options for serious mental illness.The agency stated that its decision allows the study to proceed and does not mean the drug has been approved or found to be safe or effective. FDA added that it will continue to review data as it becomes available and support efforts to develop new treatments for alcohol use disorder and other mental health conditions.<a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> is up 36% year-to-date,&nbsp;<a href="https://stocktwits.com/symbol/HELP">HELP stock</a> is down 33%, while&nbsp;<a href="https://stocktwits.com/symbol/ENVB">ENVB stock</a> is up 77%.The AdvisorShares Psychedelics ETF (PSIL) is up 68% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dan-ives-intel-comeback-rocky-balboa-ai-trade-in-third-innings/cZBWzYEReTv">Dan Ives Compares Intel's Comeback To Rocky Balboa, Says AI Trade Is In Its Third Innings — 'You Follow The Capex, That's Where Investors Are'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump signs an executive order on researching the effects of psychedelic drugs in medical treatment for veterans. (Photo by Allison Robbert/For The Washington Post via Getty Images)

FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain

The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.

Equity

Cybin Inc. (NASDAQ:HELP) Given Average Recommendation of "Buy" by Brokerages

Shares of Cybin Inc. (NASDAQ:HELP - Get Free Report) have been assigned an average recommendation of "Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. Five analysts...

Cybin (NASDAQ:HELP) Now Covered by TD Cowen

TD Cowen assumed coverage on shares of Cybin in a research report on Monday. They set a "buy" rating and a $8.00 price objective on the stock...

Cybin (NASDAQ:HELP)  Shares Down 2.1%   - Time to Sell?

Cybin (NASDAQ:HELP) Trading Down 2.1% - Here's What Happened...

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions PR Newswire VANCOUVER, BC, March 9, 2026 Issued...

<ul class="summary-bullets"><li>The stock's plunge came after Helus Pharma released results from a mid-stage trial of its anxiety drug HLP004.</li><li>The 36-patient study showed a 10.4-point drop in anxiety scores after six weeks, with 67% of participants responding to treatment.</li><li>Jefferies reiterated a 'Buy' rating and $22 price target, implying a 290% upside from current levels.</li></ul>Shares of Helus Pharma, Inc. (HELP) crashed to their worst trading day on record on Thursday after the company reported results from a mid-stage anxiety drug trial, though Jefferies sees a larger catalyst ahead that could still drive the stock sharply higher.<a href="https://stocktwits.com/symbol/HELP">HELP shares</a> plunged 34% on Thursday to end at $5.64, marking their lowest levels in nearly a year. However, the stock rose over 3% after-hours.&nbsp;<h2 class="st-heading-2">Anxiety Trial Results Trigger Sell-Off</h2>Helus Pharma reported&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/help-stock-tanks-despite-strong-phase-2-results-for-anxiety-treatment-retail-buys-the-dip-ignoring-market-s-pessimism/cZdQHEpRI3O">early results</a> from a mid-stage clinical trial testing HLP004 as a treatment for adults with moderate-to-severe anxiety who continued to have symptoms despite taking antidepressants.The study enrolled 36 patients who received two injections of HLP004 three weeks apart while continuing standard medications. Patients given a 20 mg dose saw anxiety scores drop by about 10.4 points after six weeks. At six months, 67% showed a treatment response and 39% achieved remission.The treatment targets serotonin pathways linked to brain plasticity. In a Phase 1 study using a 30 mg dose, most patients were ready to leave the clinic within about three hours, with the drug’s effects lasting roughly 90 minutes.Generalized anxiety disorder affects more than 20 million adults in the U.S., and roughly half of patients do not respond to first-line treatments, the company said.&nbsp;<h2 class="st-heading-2">Jefferies Bullish On HELP Pipeline</h2>While the anxiety study triggered the sell-off, Jefferies maintained a bullish view on the company’s broader pipeline. The brokerage reiterated a ‘Buy’ rating and a $22 price target on the stock following the data release, implying a 290% upside from current levels.The firm said HLP004 could potentially reduce anxiety symptoms rapidly and durably, and called the generalized anxiety disorder opportunity a $1 billion-plus call option, according to&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.investing.com/news/analyst-ratings/jefferies-reiterates-helus-pharma-stock-rating-on-anxiety-data-93CH-4544705">Investing</a>.&nbsp;However, the brokerage said investors are likely waiting for additional data before gaining greater confidence in the program.&nbsp;Instead, Jefferies highlighted a larger potential catalyst: the Phase 3 Approach trial evaluating Helus Pharma’s lead drug HLP003 for major depressive disorder. HLP003 is an oral drug to treat depression alongside existing medications.&nbsp;Jefferies expects the stock to surge between 100% and 200%, depending on the outcome of the Phase 3 results for HLP003, with results expected in the fourth quarter of 2026.<h2 class="st-heading-2">Depression Trial Pipeline Shows Promise</h2>Last month, results from a mid-stage clinical trial of SPL026 for major depressive disorder were published in the journal Nature Medicine. The randomized study showed a reduction in depressive symptoms within two weeks compared with patients who received a placebo.Researchers also reported that antidepressant effects began appearing as early as one week after treatment, with benefits lasting up to three months in some participants. The findings helped guide the development of Helus Pharma’s newer drug candidates, including HLP004 for anxiety and HLP003 for depression.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for HELP was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/help_ss_png_c6d1ccebbf.webp" alt="help ss.png" width="973" height="141"><figcaption>HELP sentiment and message volume as of March 5 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/macdaddy13333/message/646725489">said</a>, “Correct this is promising info but way too small of a cohort. Big news will be in the phase 3 trials, which can't come out soon enough.”<stembedurl>https://stocktwits.com/macdaddy13333/message/646725489</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Alex1710/message/646759373">said</a>, “This stock will recover, when they knocked at institutionnel doors for cash they answered come in and have a seat.”<stembedurl>https://stocktwits.com/Alex1710/message/646759373</stembedurl>HELP stock has declined 31% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

HELP stock has declined 31% year-to-date. (Photo credit: Getty Images)

HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside

Jefferies highlighted the Phase 3 Approach trial for depression drug HLP003 as the next key catalyst for the stock.

<ul class="summary-bullets"><li>U.S. stock futures stabilized late Thursday after a sharp sell-off that erased nearly 800 points from the Dow.</li><li>Eight of the 11 S&amp;P 500 sectors closed lower, with industrials, materials, consumer staples, and healthcare each falling at least 2%.</li><li>Asian stocks mostly fell at Friday's open, pulling the broader MSCI Asia Pacific Index down to its steepest weekly decline since 2020.&nbsp;</li></ul>U.S. stock futures steadied late Thursday following a sharp sell-off that wiped nearly 800 points off the Dow, as geopolitical tensions and surging crude prices kept investors on edge.As of 9.20 p.m. ET, Nasdaq 100 and S&amp;P 500 futures were up 0.1%, while Dow futures were up 0.2%.On Stocktwits, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a> was ‘neutral’ amid ‘high’ message volume, while sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> and&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust (DIA)</a> was ‘bearish’ amid ‘high’ message volume.<h2 class="st-heading-2">US Market Drivers</h2>In the prior session, the Dow Jones Industrial Average fell 1.6%. The S&amp;P 500 Index slipped 0.6, while the Nasdaq Composite dipped 0.3%.Eight of the 11 sectors in the S&amp;P 500 closed lower during the session, with industrials, materials, consumer staples, and healthcare each losing at least 2%.Energy markets remained a key driver of volatility. U.S. crude oil prices surged above $80 per barrel during Thursday’s session after Iran reportedly struck an oil tanker with a missile. West Texas Intermediate crude settled up 8.5% at $81.01 per barrel, its highest level since 2024, while Brent crude climbed nearly 5% to around $85.41.The spike in oil prices triggered sharp swings in equity markets. At one point during the session, the Dow fell more than 1,100 points, or about 2.4%, as crude prices crossed the $80 mark before recovering slightly into the close.Oil markets have been shaken by the expanding conflict in the Middle East, which has involved about a dozen countries since hostilities intensified late last month. Traffic through the Strait of Hormuz, a critical route that handles roughly one-fifth of the world’s oil supply, has slowed amid rising security risks.Mohamed El-Erian&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/elerianm/status/2029646631725887998">said on X</a> that the situation involves key market “guardrails” that are currently under stress and warned that if they fail to hold, “the economic and financial dynamics could shift from the more predictable mean reversion to the more uncertain ‘multiple equilibria.’”Meanwhile, investors are also monitoring policy developments in Washington. Treasury Secretary Scott Bessent said the Trump administration’s newly announced 15% global tariff is expected to take effect this week.Despite the broader decline in equities, Berkshire Hathaway stood out as a rare gainer, rising nearly 3% after the company said it has resumed share repurchases for the first time since 2024. CEO Greg Abel also purchased about $15 million worth of company stock.<h2 class="st-heading-2">Trending Stocks To Watch On NYSE, Nasdaq</h2>Indonesia Energy Corp (INDO), Battalion Oil Corp (BATL), United States Oil Fund (USO): INDO rose over 1% in extended trading, while BATL jumped nearly 16%, as oil prices headed for their&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/indo-batl-uso-in-focus-oil-rally-middle-east-war-1b-fuel-bill/cZdhSDMRIEc">biggest weekly gain</a> since 2022. USO climbed to its highest level in six years.Marvell Technology (MRVL): Shares surged about 15% after-hours as the company issued first-quarter fiscal 2027&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mrvl-shares-surge-on-solid-q1-2027-guidance/cZdX3fORI3x">revenue guidance</a> above Wall Street estimates and projected full-year revenue growth of more than 30%.Costco Wholesale (COST): Shares slipped slightly in extended trading despite the warehouse retailer reporting&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/costco-q2-sales-growth-trails-wall-street-expectations/cZdX3ouRI3U">second-quarter earnings</a> and revenue that topped analyst estimates.Helus Pharma (HELP): Shares plunged 34% in Thursday’s session, marking their worst trading day on record, after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/help-stock-tanks-despite-strong-phase-2-results-for-anxiety-treatment-retail-buys-the-dip-ignoring-market-s-pessimism/cZdQHEpRI3O">Phase 2 results</a> for its anxiety treatment HLP004 disappointed investors.Newsmax (NMAX): Shares headed for their&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/newsmax-stock-heads-for-best-week-since-ipo/cZdhkXqRIE2">best weekly performance</a> since the company’s IPO following strong viewership numbers tied to its coverage of President Donald Trump’s State of the Union address.<h2 class="st-heading-2">How Global Markets Are Performing Today</h2>In broader markets, the yield on the benchmark 10-year U.S. Treasury note was around 4.14%, while gold traded near $5,093 an ounce in early Asian trading. Silver was near $82.47, while platinum and palladium also moved higher.Asian markets were lower on Friday, with stocks in Japan, South Korea and Australia falling at the open, pulling the broader MSCI Asia Pacific Index down about 0.6%. The index has dropped roughly 6.7% since the war began, marking its steepest weekly decline since 2020.Among the catalysts for the day are the U.S. employment report, retail sales data, business inventories and consumer credit figures, along with remarks from Federal Reserve officials Mary Daly and Beth Hammack.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Dow Jones Industrial Average closes above the 50,000 mark for the first time ever, seen in this photo illustration in Brussels, Belgium, on February 7, 2026. (Photo Illustration by Jonathan Raa/NurPhoto via Getty Images)

Dow Futures Hold Ground After 800-Point Selloff As Oil Surge Hits Wall Street: Why MRVL, USO, COST, HELP Are Trending After-Hours

U.S. crude surged above $80 per barrel after a reported Iranian missile strike on an oil tanker.

Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints

Helus Pharma (Cybin) shares fall after Phase 2 anxiety drug results show symptom improvement, but pressure on the stock.read more...

Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion

Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion PR Newswire NEW YORK, March 5, 2026 GAD...

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.81	--	--	N/A
Q3 '25	-$0.76	-$1.00	-31.58%	MISSED

HELP
Helus Pharma Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest HELP News

HELPHelus Pharma Inc.